Characterization of Naturally-Occurring Humoral Immunity to AAV in Sheep
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
AAV vectors have shown great promise for clinical gene therapy (GT), but pre-existing human immunity against the AAV capsid often limits transduction. Thus, testing promising AAV-based GT approaches in an animal model with similar pre-existing immunity could better predict clinical outcome. Sheep have long been used for basic biological and preclinical studies. Moreover, we have re-established a line of sheep with severe hemophilia A (HA). Given the impetus to use AAV-based GT to treat hemophilia, we characterized the pre-existing ovine humoral immunity to AAV. ELISA revealed naturally-occurring antibodies to AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9. For AAV2, AAV8, and AAV9 these inhibit transduction in a luciferase-based neutralization assay. Epitope mapping identified peptides that were common to the capsids of all AAV serotypes tested (AAV2, AAV5, AAV8 and AAV9), with each animal harboring antibodies to unique and common capsid epitopes. Mapping using X-ray crystallographic AAV capsid structures demonstrated that these antibodies recognized both surface epitopes and epitopes located within regions of the capsid that are internal or buried in the capsid structure. These results suggest that sheep harbor endogenous AAV, which induces immunity to both intact capsid and to capsid epitopes presented following proteolysis during the course of infection. In conclusion, their clinically relevant physiology and the presence of naturally-occurring antibodies to multiple AAV serotypes collectively make sheep a unique model in which to study GT for HA, and other diseases, and develop strategies to circumvent the clinically important barrier of pre-existing AAV immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“because a high level of naturally occurring anti-AAV2 antibodies was previously reported in sheep [22].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
A Viral Phospholipase A2 Is Required for Parvovirus Infectivity
Zádori, Z., Szelei, J., Lacoste, M.-C., Li, Y., Gariépy, S., Raymond, P., Allaire, M., Nabi, I. R., & Tijssen, P. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00031-4 · Cited by 518
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390
Self-citationIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Opie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 3×
“For example, peptide 97 for AAV2 (Figure 4) overlaps with the epitope for AAV2 conformational antibody C37-B reported to block receptor attachment [37].”
BackgroundResultScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 255
Self-citationMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253 · cited 3×
“Epitopes previously identified in Moskalenko, et al [43] are listed as MK.”
BackgroundInfluentialImmune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Li, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Self-citationAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215 · cited 1×
“permitting some degree of tissue-targeting [4-7].”
Self-citationWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205
Self-citationLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 1×
“However, consistent with the recognition of the AAV capsids in the ELISA and neutralization assay results, a number of the peptides recognized were located on the capsid surface and in regions analogous to previously mapped neutralizing antigenic epitopes in AAV2 and in AAV8 [35-37] (Table 1, Figures 4A, 4C, 4E and 4G…”
ResultDirected evolution of adeno-associated virus to an infectious respiratory virus
Excoffon, K. J. D. A., Koerber, J. T., Dickey, D. D., Murtha, M., Keshavjee, S., Kaspar, B. K., Zabner, J., & Schaffer, D. V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813365106 · Cited by 181
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170 · cited 3×
“of antibodies to a limited number of AAV serotypes [24],”
BackgroundNathwani, A. C., Davidoff, A. M., Hanawa, H., Hu, Y., Hoffer, F. A., Nikanorov, A., Slaughter, C., Ng, C. Y. C., Zhou, J., Lozier, J. N., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0589 · Cited by 164
Grieger, J. C., & Samulski, R. J. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_005 · Cited by 159
Adeno-associated viral vectors as gene delivery vehicles.
Carter, P. J., & Samulski, R. J. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.6.1.17 · Cited by 155
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155 · cited 2×
“Because genomic integration of AAV vectors is rare [8-11], the risk of insertional mutagenesis with AAV vectors is greatly reduced compared to retroviruses.”
ResultHurlbut, G. D., Ziegler, R. J., Nietupski, J. B., Foley, J. W., Woodworth, L. A., Meyers, E., Bercury, S. D., Pande, N. N., Souza, D. W., Bree, M. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.175 · Cited by 142
Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid
Bell, C. L., Gurda, B. L., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.00448-12 · Cited by 138
Self-citationAdeno-Associated Viral Vectors for Gene Transfer and Gene Therapy
Büeler, H. (1999) · Biological Chemistry · doi:10.1515/bc.1999.078 · Cited by 110
Popa-Wagner, R., Porwal, M., Kann, M., Reuss, M., Weimer, M., Florin, L., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00282-12 · Cited by 109
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Self-citationVeron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
White, J. D., Thesier, D. M., Swain, J. B. D., Katz, M. G., Tomasulo, C., Henderson, A., Wang, L., Yarnall, C., Fargnoli, A., Sumaroka, M., et al. (2011) · Gene Therapy · doi:10.1038/gt.2010.168 · Cited by 73
Vandenberghe, L., & Wilson, J. (2007) · Current Gene Therapy · doi:10.2174/156652307782151416 · Cited by 68
Clinical and molecular characterization of a re‐established line of sheep exhibiting hemophilia A
Porada, C. D., Sanada, C. D., Long, C. R., WOOD, J. A., DESAI, J., Frederick, N. M., Millsap, L., Bormann, C. L., Menges, S., Hanna, C. B., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03697.x · Cited by 66
Self-citationMariani, J. A., Smolic, A., Preovolos, A., Byrne, M. J., Power, J. M., & Kaye, D. M. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq234 · Cited by 59
Immune Responses to AAV Capsid: Are Mice Not Humans After All?
Herzog, R. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300123 · Cited by 56
AAV serotype influences gene transfer in corneal stroma in vivo
Sharma, A., Tovey, J. C. K., Ghosh, A., & Mohan, R. R. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.06.020 · Cited by 51
Lochrie, M. A., Tatsuno, G. P., Arbetman, A. E., Jones, K., Pater, C., Smith, P. H., McDonnell, J. W., Zhou, S., Kachi, S., Kachi, M., et al. (2006) · Virology · doi:10.1016/j.virol.2006.05.023 · Cited by 48
David, A. L., McIntosh, J., Peebles, D. M., Cook, T., Waddington, S., Weisz, B., Wigley, V., Abi-Nader, K., Boyd, M., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.007 · Cited by 47
Li, H., Lin, S.-W., Giles-Davis, W., Li, Y., Zhou, D., Xiang, Z. Q., High, K. A., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.79 · Cited by 46
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Humoral Immunity to AAV-6, 8, and 9 in Normal and Dystrophic Dogs
Shin, J.-H., Yue, Y., Smith, B., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.125 · Cited by 33
Isolation of an adeno associated virus from sheep
Clarke, J. K., McFerran, J. B., McKillop, E. R., & Curran, W. L. (1979) · Archives of Virology · doi:10.1007/bf01348034 · Cited by 26
Karman, J., Gumlaw, N. K., Zhang, J., Jiang, J.-L., Cheng, S. H., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034684 · Cited by 25
Nathwani, A., Tuddenham, E., Rosales, C., McIntosh, J., Riddell, A., Rustagi, P., Glader, B., Kay, M., Allay, J., Coleman, J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.248.248 · Cited by 24
Ito, T., Yamamoto, S., Hayashi, T., Kodera, M., Mizukami, H., Ozawa, K., & Muramatsu, S.-I. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.009077 · Cited by 24
Jiménez‐Clavero, M. Á., Douglas, A., Lavery, T., Ranea, J. A. G., & Ley, V. (2000) · Virology · doi:10.1006/viro.2000.0256 · Cited by 23
Binny, C., & Nathwani, A. C. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-873-3_6 · Cited by 12
A Novel Strategy to Circumvent Pre-Existing Humoral Immunity to AAV
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y.-F., Davidson, R. J., Hui, D. J., Hinderer, C. J., Faella, A., Howard, C., Tai, A., et al. (2012) · Blood · doi:10.1182/blood.v120.21.2050.2050 · Cited by 5
113. Characterization of Porcine Adeno-Associated Viruses Belonging to Unique Clades
(2012) · Molecular Therapy · doi:10.1016/s1525-0016(16)35917-2 · Cited by 1
Research works printed but not linked: 1
- A Nathwani, 2010, Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B, Blood, 116, 248a, 10.1182/blood.V116.21.248.248 · DOI · Paper page
Cited by
Thwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“Similarly, naturally-occurring antibodies to various AAV serotypes have been found in sheep (Tellez et al., 2013), thus potentially affecting the development of gene therapy in this large animal model of achromatopsia (Banin et al.”
BackgroundRoss, M., Obolensky, A., Averbukh, E., Ezra-Elia, R., Yamin, E., Honig, H., Dvir, H., Rosov, A., Hauswirth, W. W., Gootwine, E., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.023 · Cited by 16
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00495-5 · Cited by 3
Metadata
- Authors
- Tellez, J., Van Vliet, K., Tseng, Y.-S., Finn, J. D., Tschernia, N., Almeida-Porada, G., Arruda, V. R., Agbandje-McKenna, M., & Porada, C. D.
- Affiliations
- University of Nevada, Reno (US)
- University of Florida (US)
- Children's Hospital of Philadelphia (US)
- Wake Forest University (US)
- Corresponding author
- Porada, Christopher D.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-24
- Volume
- 8
- Issue
- 9
- Pages
- e75142
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3782463
- OpenAlex
- W2024568218
- Cited by
- 18
- References
- 57
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 3 · 2019: 3 · 2017: 1 · 2016: 2 · 2014: 1
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wake Forest University
- National Institutes of Health (NIH-R01)
- National Heart, Lung, and Blood Institute (P01HL064190)
- National Institute of General Medical Sciences (R01GM082946)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD43038, R01HD043038)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, humoral immunity, sheep, pre-existing antibodies, AAV capsid, hemophilia A, gene therapy, neutralizing antibodies, epitope mapping, AAV serotypes, animal models
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Epitopes, Capsid, Enzyme-Linked Immunosorbent Assay, Luciferases, Neutralization Tests, Sheep, Genetic Therapy, Crystallography, X-Ray, Models, Animal, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.